• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

370
58
43
41
20

COUNTRY

40
8
5
5
4

PRICE

136
413
509
1,026

PUBLISHED

16
60
287
1,026

PRODUCT TYPE

993
17
11
4
1

Central Nervous System

In 2012 major changes might revolutionize the treatment of multiple sclerosis, as Gilenya, the first novel drug in five years, will be joined by three new products: BG-12, Aubagio, and Lemtrada. Recent exciting developments in drug discovery might also enhance the hopes of those fighting against Alzheimer.

Great commercial and scientific opportunities are to be found in similar battles against a range of diseases and neurodegenerative disorders, e.g. Parkinson’s disease, schizophrenia, migraine, insomnia, epilepsy, etc.

A wide selection of industry reports, scientific journals and academic textbooks in this section allow readers to explore every conceivable facet of this industry, such as market trends, industry forecasts, new drugs in development, the latest research & development, patent applications, and licensing strategies.

Key players featured in our publications include Biogen Idec, Sanofi, Genzyme, and many more. Show Less
Read more

PRODUCT TITLE

Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022

Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its...

February 2014
FROM

Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022

Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms,...

February 2014
FROM

PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022

PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core...

February 2014
FROM

Abilify (Schizophrenia) - Forecast and Market Analysis to 2022

Abilify (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms,...

February 2014
FROM

Bitopertin (Schizophrenia) - Forecast and Market Analysis to 2022

Bitopertin (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms,...

February 2014
FROM

Zyprexa (Schizophrenia) - Forecast and Market Analysis to 2022

Zyprexa (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms,...

February 2014
FROM

Fanapt (Schizophrenia) - Forecast and Market Analysis to 2022

Fanapt (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms,...

February 2014
FROM

Saphris (Schizophrenia) - Forecast and Market Analysis to 2022

Saphris (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms,...

February 2014
FROM

Geodon (Schizophrenia) - Forecast and Market Analysis to 2022

Geodon (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms,...

February 2014
FROM

Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022

Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms,...

February 2014
FROM

PharmaPoint: Schizophrenia - US Drug Forecast and Market Analysis to 2022

PharmaPoint: Schizophrenia - US Drug Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core...

February 2014
FROM

Seroquel (Schizophrenia) - Forecast and Market Analysis to 2022

Seroquel (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms,...

February 2014
FROM

Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022

Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms,...

February 2014
FROM

Latuda (Schizophrenia) - Forecast and Market Analysis to 2022

Latuda (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms,...

February 2014
FROM

EpiCast Report: Major Depressive Disorder - Epidemiology Forecast to 2023

EpiCast Report: Major Depressive Disorder - Epidemiology Forecast to 2023 Summary Major depressive disorder (MDD), also known as clinical depression or major depression, is widely recognized as one...

February 2014
FROM

EpiCast Report: Migraine - Epidemiology Forecast to 2023

EpiCast Report: Migraine - Epidemiology Forecast to 2023 Summary Migraine is typically characterized by recurring headaches, throbbing pain on one side of the head along with one or more of the following...

February 2014
FROM

Mental Health and Work: United Kingdom

Tackling mental ill-health of the working-age population is becoming a key issue for labour market and social policies in OECD countries OECD governments increasingly recognise that policy has a major...

February 2014
FROM

Batten Disease - Pipeline Review, H1 2014

Batten Disease - Pipeline Review, H1 2014 Summary Global Markets Direct’s, 'Batten Disease - Pipeline Review, H1 2014', provides an overview of the indication’s therapeutic pipeline. This report provides...

January 2014
FROM

Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014

Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014 Summary Global Markets Direct’s, 'Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014', provides an overview of the indication’s therapeutic...

January 2014
FROM

Mental Health and Work: Switzerland

Tackling mental ill-health of the working-age population is becoming a key issue for labour market and social policies in OECD countries OECD governments increasingly recognise that policy has a major...

January 2014
FROM
Loading Indicator

Our Clients

Our clients' logos